Cost-Effective Scaling of Cell Therapies: Vertical-Wheel Bioreactors vs Traditional Systems
This white paper examines the economic and operational advantages of Vertical-Wheel® Bioreactors compared with planar culture and conventional stirred-tank systems for cell therapy manufacturing. Key cost drivers include expansion efficiency, labor, facility footprint, process scalability, batch reproducibility, and product quality. Published examples demonstrate increased cell yield, fewer processing steps, reduced labor, and improved facility utilization through single-use, closed-system operation. Low-shear, homogeneous hydrodynamics support consistent growth and critical quality attributes, positioning Vertical-Wheel® Technology as a scalable approach for reducing cost of goods.
This application note demonstrates the benefits of PBS Biotech’s PBS-Mini Vertical-Wheel® Bioreactor within a scalable workflow developed with Bio-Techne for hiPSC expansion and differentiation into functional pancreatic islet-like clusters. The bioreactor supported robust aggregate culture while maintaining more than 95% pluripotency during hiPSC expansion and supporting progression through key stages of pancreatic differentiation. Combined with Bio-Techne’s GMP-grade reagents and analytical solutions, the workflow generated beta cell-containing, functional islet-like clusters that…
This webinar examines scalable suspension culture of PSC-derived organoids using PBS Biotech Vertical-Wheel bioreactors. PBS Applications Engineer, Hannah Worden, explains how low-shear, homogeneous mixing and consistent geometry support organoid process development and scale-up. Case studies cover liver, pancreatic islet, and cerebellar organoids, including aggregate-size control, differentiation, functional markers, and improved organization under dynamic culture. With the audience, we address agitation, seeding density, media formulation, perfusion-based medium exchange, sampling, and…
This presentation, presented at ISSCR Kyoto 2026 explores how Vertical-Wheel Bioreactors can reduce development and manufacturing risk for PSC therapies by providing a scalable platform from process development through commercial production. It highlights global clinical trials supported by Vertical-Wheel technology, predictive scale-down with MiniPRO, controlled hydrodynamics, automation, and linear scale-up through PBS-80. Data demonstrate consistent PSC growth across scales, culminating in greater than 200 billion cells from a 50 L batch while maintaining pluripotency, illustrating a…
How Can We Help?
Tell us what you need and we’ll take it from there.